TherapeuticsMD, Inc. (NYSE MKT: TXMD) (the “Company”) announced today the pricing of an underwritten public offering of approximately 8.6 million shares of its common stock, offered at a price of $4.67 per share. The gross proceeds to the Company from this offering are expected to be approximately $40.0 million, before deducting underwriting discounts, commissions and other estimated offering expenses payable by the Company. All of the shares in the offering are to be sold by the Company. In addition, the Company has granted the underwriters an option for a period of 30 days to purchase, at the public offering price less the underwriting discount, up to approximately 1.3 million additional shares of its common stock. The offering is expected to close on or about August 4, 2014, subject to the satisfaction of customary closing conditions.
Goldman, Sachs & Co. is acting as sole book-running manager for the offering and Noble Financial Capital Markets is acting as co-manager for the offering.
The Company has filed a shelf registration statement on Form S-3, including a prospectus supplement and accompanying prospectus, with the Securities and Exchange Commission, or SEC, relating to the public offering of the shares of common stock described above. Before buying any shares of the Company’s common stock in the offering, you should carefully read the prospectus supplement and the accompanying prospectus, together with the information incorporated therein. These documents contain important information that you should consider when making your investment decision. The Company’s SEC filings are available to the public from the SEC’s website at www.sec.gov. Alternatively, you may request the prospectus supplement and accompanying prospectus by contacting Goldman, Sachs & Co., Prospectus Department, 200 West Street, New York, NY 10282, by calling (866) 471-2526, or by emailing firstname.lastname@example.org, or by contacting Noble Financial Capital Markets, 951 Yamato Road, Suite 100, Boca Raton, Florida 33431, by calling (561) 998-5480, or by emailing email@example.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV